The Joint Corp.

Equities

JYNT

US47973J1025

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 03:02:14 2024-03-28 pm EDT 5-day change 1st Jan Change
13.04 USD +2.11% Intraday chart for The Joint Corp. +1.79% +36.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : The Joint Corp., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (JYNT) THE JOINT Reports Q4 Revenue $30.6M, vs. Street Est of $29.1M MT
The Joint Corp. Provides Sales Guidance for the Year 2024 CI
The Joint Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
The Joint Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
B. Riley Lowers The Joint's Price Target to $12 From $27 After Mixed Q3 Results; Maintains Buy Rating MT
Transcript : The Joint Corp., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (JYNT) THE JOINT Reports Q3 Revenue $29.5M, vs. Street Est of $28.8M MT
The Joint Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
The Joint Corp. Reiterates Revenue Guidance for the Year 2023 CI
The Joint Corp. Appoints Jeff Gramm to the Board of Directors, Effective January 2, 2024 CI
Joint Corp. Insider Bought Shares Worth $716,614, According to a Recent SEC Filing MT
Roth MKM Adjusts Price Target on Joint to $13 From $16, Keeps Buy Rating MT
The Joint's Q2 Sales Shy of Forecast, Cuts Full-Year Revenue, Adjusted EBITDA Guidance; Shares Drop After Hours MT
Transcript : The Joint Corp., Q2 2023 Earnings Call, Sep 13, 2023
The Joint Corp. Revises Earnings Guidance for the Year 2023 CI
The Joint Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Joint Receives Nasdaq Delinquency Notification Letter MT
The Joint Corp. Appoints Lori Abou Habib as New Chief Marketing Officer CI
Maxim Downgrades Joint to Hold From Buy MT
Transcript : The Joint Corp., Q2 2023 Earnings Call, Aug 10, 2023
The Joint Opens Clinic in Texarkana, Texas MT
The Joint Corp. Names Official Chiropractic and Official Partner of the Tampa Bay Buccaneers CI
The Joint Acquires Wisconsin Regional Developer Territory Rights for $950,000 MT
B. Riley Lifts Joint's Price Target to $27 From $26, Keeps Buy Rating MT
Chart The Joint Corp.
More charts
The Joint Corp. is an operator, manager and franchisor of chiropractic clinics that uses a private pay, non-insurance, cash-based model. The Company operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment is comprised of the operating activities of the Company-owned or managed clinics. The Company operates or manages approximately 135 clinics under this segment. The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The franchise system consists of approximately 800 clinics in operation. It offers a range of membership and wellness packages. It offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
12.77 USD
Average target price
12.19 USD
Spread / Average Target
-4.56%
Consensus
  1. Stock
  2. Equities
  3. Stock The Joint Corp. - Nasdaq
  4. News The Joint Corp.
  5. Earnings Flash (JYNT) THE JOINT CORPORATION Reports Q2 Revenue $25.1M